Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Objective: Our objective was to examine perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness ratios (ICERs). Methods: We analyzed the Tufts Medical Center’s CEA and Global Health CEA registries, containing 6907 cost-per-quality-adjusted-life-year (QALY) and 698 cost-per-disability-adjusted-life-year (DALY) studies published through 2018. We examined how often published CEAs included non-health consequences and their impact on ICERs. We also reviewed 45 country-specific guidelines to examine recommended analytic perspectives. Results: Study authors often mis-specified or did not clearly state the perspective used. After re-classification by registry reviewers, a healthcare sector or payer perspective was most prevalent (74%). CEAs rarely included unrelated medical costs and impacts on non-healthcare sectors. The most common non-health consequence included was productivity loss in the cost-per-QALY studies (12%) and patient transportation in the cost-per-DALY studies (21%). Of 19,946 cost-per-QALY ratios, the median ICER was $US26,000/QALY (interquartile range [IQR] 2900–110,000), and 18% were cost saving and QALY increasing. Of 5572 cost-per-DALY ratios, the median ICER was $US430/DALY (IQR 67–3400), and 8% were cost saving and DALY averting. Based on 16 cost-per-QALY studies (2017–2018) reporting 68 ICERs from both the healthcare sector and societal perspectives, the median ICER from a societal perspective ($US22,710/QALY [IQR 11,991–49,603]) was more favorable than from a healthcare sector perspective ($US30,402/QALY [IQR 10,486–77,179]). Most governmental guidelines (67%) recommended either a healthcare sector or a payer perspective. Conclusion: Researchers should justify and be transparent about their choice of perspective and costing approaches. The use of the impact inventory and reporting of disaggregate outcomes can reduce inconsistencies and confusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 1×
“A major change in the Second Panel’s guideline includes two reference case analyses, from both a healthcare sector and a societal perspective [10].”
BackgroundSelf-citationCost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
Accounting for future costs in medical cost-effectiveness analysis
Meltzer, D. (1997) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00507-3 · Cited by 444
Wilkinson, T., Sculpher, M. J., Claxton, K., Revill, P., Briggs, A., Cairns, J. A., Teerawattananon, Y., Asfaw, E., Lopert, R., Culyer, A. J., et al. (2016) · Value in Health · doi:10.1016/j.jval.2016.04.015 · Cited by 327
Garrison, L. P., Pauly, M. V., Willke, R. J., & Neumann, P. J. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.006 · Cited by 188
Self-citationKrol, M., Papenburg, J., & van Exel, J. N. A. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0218-y · Cited by 159
Costing and Perspective in Published Cost-Effectiveness Analysis
Neumann, P. J. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819bc09d · Cited by 143
Self-citationKrol, M., Papenburg, J., Koopmanschap, M. A., & Brouwer, W. B. F. (2011) · PharmacoEconomics · doi:10.2165/11539970-000000000-00000 · Cited by 141
Cited by
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.10.008 · Cited by 847
Cost data in implementation science: categories and approaches to costing
Gold, H. T., McDermott, C., Hoomans, T., & Wagner, T. H. (2022) · Implementation Science · doi:10.1186/s13012-021-01172-6 · Cited by 152
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Self-citationSivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2362278 · Cited by 15
Kazi, D. S., Abdullah, A. R., Arnold, S. V., Basu, A., Bellows, B. K., Breathett, K., Chew, D. S., Cohen, D. J., DeJong, C., Heidenreich, P. A., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.05.009 · Cited by 14
Metadata
- Authors
- Kim, D. D., Silver, M. C., Kunst, N., Cohen, J. T., Ollendorf, D. A., & Neumann, P. J.
- Venue
- PharmacoEconomics
- Published
- 2020-10
- Volume
- 38
- Issue
- 10
- Pages
- 1135-1145
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- OpenAlex
- W3045346667
- Cited by
- 277
- References
- 50
- FWCI
- 27.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. https://app.cochat.ai/papers/10.1007/s40273-020-00942-2
- The paper
- Kim, D. D., Silver, M. C., Kunst, N., Cohen, J. T., Ollendorf, D. A., & Neumann, P. J. (2020). Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. PharmacoEconomics. https://doi.org/10.1007/s40273-020-00942-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.